Buy Rating for Larimar Therapeutics Driven by Promising Data and Unmet Need in Friedreich’s Ataxia

LifeSci Capital analyst Cory Jubinville, PhD has maintained their bullish stance on LRMR stock, giving a Buy rating today.

Cory Jubinville, PhD has given his Buy rating due to a combination of factors including promising clinical data and the unmet medical need in Friedreich’s ataxia (FA). The recent data from Larimar Therapeutics’ ongoing open-label extension study showed that all patients receiving the 50 mg dose of nomlabofusp exhibited significant improvements in key clinical metrics, such as FXN levels and mFARS scores, which are crucial indicators of the drug’s efficacy.
Despite concerns over the incidence of anaphylaxis at treatment initiation, the potential benefits of nomla appear to outweigh these risks, especially given the severe progression of FA without treatment. The positive sentiment from FA clinicians, who largely support nomla’s risk/benefit profile, further underscores the drug’s potential. This support suggests that the medical community is optimistic about nomla’s ability to address the significant quality of life challenges faced by FA patients, which contributes to the Buy rating.